Biolegend, 505830, Brilliant Violet 421™ anti-mouse IFN-γ Antibody, 50μg

IFN-γ is a potent multifunctional cytokine which is secreted primarily by activated NK cells and T cells. Originally characterized based on anti-viral activities, IFN-γ also exerts anti-proliferative, immunoregulatory, and proinflammatory activities. IFN-γ can upregulate MHC class I and II antigen expression by antigen-presenting cells.
50μg
Verified Reactivity: Mouse
Antibody Type: Monoclonal
Host Species: Rat
Immunogen: E. coli-expressed, recombinant mouse IFN-γ
Formulation: Phosphate-buffered solution, pH 7.2, containing 0.09% sodium azide and BSA (origin USA).
Preparation: The antibody was purified by affinity chromatography and conjugated with Brilliant Violet 421™ under optimal conditions.
Concentration: µg sizes: 0.2 mg/mLµL sizes: lot-specific (to obtain lot-specific concentration and expiration, please enter the lot number in our Certificate of Analysis online tool.)
Storage & Handling: The antibody solution should be stored undiluted between 2°C and 8°C, and protected from prolonged exposure to light. Do not freeze.
Application: ICFC - Quality tested
Recommended Usage: Each lot of this antibody is quality control tested by immunofluorescent staining with flow cytometric analysis. For immunofluorescent staining using the µg size, the suggested use of this reagent is ≤0.1 µg per million cells in 100 µl volume. For immunofluorescent staining using the µl size, the suggested use of this reagent is 5 µl per million cells in 100 µl staining volume or 5 µl per 100 µl of whole blood. It is recommended that the reagent be titrated for optimal performance for each application.Brilliant Violet 421™ excites at 405 nm and emits at 421 nm. The standard bandpass filter 450/50 nm is recommended for detection. Brilliant Violet 421™ is a trademark of Sirigen Group Ltd.Learn more about Brilliant Violet™. This product is subject to proprietary rights of Sirigen Inc. and is made and sold under license from Sirigen Inc. The purchase of this product conveys to the buyer a non-transferable right to use the purchased product for research purposes only. This product may not be resold or incorporated in any manner into another product for resale. Any use for therapeutics or diagnostics is strictly prohibited. This product is covered by U.S. Patent(s), pending patent applications and foreign equivalents.
Excitation Laser: Violet Laser (405 nm)
Application Notes: ELISA1-4,11,14 or ELISPOT5 Detection: The biotinylated XMG1.2 antibody is useful as a detection antibody for a sandwich ELISA or ELISPOT assay, when used in conjunction with purified R4-6A2 antibody (Cat. No. 505702/505706) as the capture antibody and recombinant mouse IFN-γ (Cat. No. 575309) as the standard. ELISA or ELISPOT Capture: The purified XMG1.2 antibody is useful as a capture antibody for a sandwich ELISA or ELISPOT assay, when used in conjunction with biotinylated R4-6A2 antibody (Cat. No. 505704) as the detection antibody and recombinant mouse IFN-γ (Cat. No. 575309) as the standard. The LEAF™ purified antibody is suggested for ELISPOT capture (Cat. No. 505812). Flow Cytometry7,8,12,13,16: The fluorochrome-labeled XMG1.2 antibody is useful for intracellular immunofluorescent staining and flow cytometric analysis to identify IFN-γ-producing cells within mixed cell populations. Neutralization1-3,9,10: The XMG1.2 antibody can neutralize the bioactivity of natural or recombinant IFN-γ. The LEAF™ purified antibody (Endotoxin <0.1 EU/µg, Azide-Free, 0.2 µm filtered) is recommended for neutralization of mouse IFN-γ bioactivity in vivo and in vitro (Cat. No. 505812). For in vivo studies or highly sensitive assays, we recommend Ultra-LEAF™ purified antibody (Cat. No. 505834) with a lower endotoxin limit than standard LEAF™ purified antibodies (Endotoxin <0.01 EU/µg). Additional reported applications (for the relevant formats) include: Western blotting, immunohistochemical staining of frozen tissue sections6,22,23, and immunocytochemistry. Note: For testing mouse IFN-γ in serum, plasma or supernatant, BioLegend's ELISA Max™ Sets (Cat. No. 430801 to 430806) are specially developed and recommended.
Application References(PubMed link indicates BioLegend citation): Abrams J, et al. 1992. Immunol. Rev. 127:5. (ELISA, Neut) Sander B, et al. 1993. J. Immunol. Meth. 166:201. (ELISA, Neut) Abrams J, et al. 1995. Curr. Prot. Immunol. John Wiley and Sons, New York. Unit 6.20. (ELISA, Neut) Yang X, et al. 1993. J. Immunoassay 14:129. (ELISA) Klinman D, et al. 1994. Curr. Prot. Immunol. John Wiley and Sons, New York. Unit 6.19. (ELISPOT) Sander B, et al. 1991. Immunol. Rev. 119:65. (IHC) Ferrick D, et al. 1995. Nature 373:255. (FC) Ko SY, et al. 2005. J. Immunol. 175:3309. (FC) PubMed Peterson KE, et al. 2000. J. Virol. 74:5363. (Neut) DeKrey GK, et al. 1998. Infect. Immun. 66:827. (Neut) Dzhagalov I, et al. 2007. J. Immunol. 178:2113. (ELISA) Lawson BR, et al. 2007. J. Immunol. 178:5366. (FC) Lee JW, et al. 2006. Nature Immunol. 8:181. (FC) PubMed Xu G, et al. 2007. J. Immunol. 179:5358. (ELISA) PubMed Montfort M, et al.2004. J. Immunol. 173:4084. PubMed Haring JS, et al. 2008. J. Immunol. 180:2855. (FC) PubMed Jordan JM, et al. 2008. Infect Immun. 76:3717. PubMed Tonkin DR, et al. 2008. J. Immunol. 181:4516. PubMed Charles N, et al. 2010. Nat. Med. 16:701. (FC) PubMed Cui Y, et al. 2009. Invest. Ophth. Vis. Sci. 50:5811. (FC) PubMed Mykkanen OT, et al. 2014. PLoS One. 9:114790. PubMed Yokogawa M, et al. 2013. Mol. Carcinog. 52:760. (IHC) Mottram PL, et al. 1998. J Immunol. 161:602. (IHC)
Product Citations: Harsha Krovi S, et al. 2020. Nat Commun. 4.790277778. PubMed Soon MSF, et al. 2020. Nat Immunol. 1.984027778. PubMed Wang X, et al. 2019. Cell Res. 29:787. PubMed Aso K, et al. 2023. Nat Commun. 14:984. PubMed Li X, et al. 2023. J Clin Invest. 133:. PubMed Rabia E, et al. 2023. Front Immunol. 14:1168444. PubMed Denny L, et al. 2021. Clin Transl Immunology. 10:e1234. PubMed Ozga AJ, et al. 2022. Immunity. 55:82. PubMed Kim E, et al. 2022. Immunity. 55:145. PubMed Su C, et al. 2022. NPJ Vaccines. 7:168. PubMed Zhao Q, et al. 2023. Nutrients. 15: . PubMed Zhang B, et al. 2023. Signal Transduct Target Ther. 8:28. PubMed Xu R 2023. Cell Reports. 42(2):112054. PubMed Ninnemann J, et al. 2022. Mucosal Immunol. 15:698. PubMed Weulersse M, et al. 2020. Immunity. 53(4):824-839.e10. PubMed Singer M et al. 2016. Cell. 166(6):1500-1511 . PubMed Page N, et al. 2018. Immunity. 48:937. PubMed Quatrini L, et al. 2018. Nat Immunol. 19:954. PubMed Manivasagam S, et al. 2022. J Immunol. 208:1341. PubMed Gruber T, et al. 2020. JCI Insight. 5:00. PubMed Kremenovic M, et al. 2022. J Immunother Cancer. 10:. PubMed Feizi N, et al. 2021. Cell Death Dis. 12:1026. PubMed Peng Z, et al. 2021. STAR Protocols. 2(2):100595. PubMed Jtte BB, et al. 2021. iScience. 24(8):102833. PubMed Wang W, et al. 2020. Br J Pharmacol. 177:5569. PubMed Gajdasik DW, et al. 2020. Nat Commun. 2.834027778. PubMed Runge EM, et al. 2020. J Neuroinflammation. 17:121. PubMed Perrot I et al. 2019. Cell Rep. 27(8):2411-2425 . PubMed Jia L, et al. 2022. Front Immunol. 13:897879. PubMed Rao TN, et al. 2020. J Immunol. 204:2600. PubMed van der Lelie D, et al. 2021. Nat Commun. 12:3105. PubMed Snyder LM, et al. 2022. Immunohorizons. 6:660. PubMed Bunn P, et al. 2014. J Immunol. 192:3709. PubMed Lian J, et al. 2020. Cell Reports. 31(8):107679. PubMed Imani J, et al. 2021. JCI Insight. 6:. PubMed Du Y, et al. 2022. Nat Commun. 13:231. PubMed Kim E, et al. 2022. STAR Protoc. 3:101366. PubMed Novince CM, et al. 2017. Sci Rep. 7:5747. PubMed Bankoti R, et al. 2017. Sci Rep. 10.1038/s41598-017-12171-3. PubMed Luck H, et al. 2015. Cell Metab. 21 527 . PubMed Liu S, et al. 2020. Cell Host & Microbe. 26(6):779-794.e8.. PubMed Gebre MS, et al. 2022. NPJ Vaccines. 7:88. PubMed Ying Zhang et al. 2017. Cancer cell. 32(3):377-391 . PubMed Pathania AS, et al. 2022. Mol Ther Oncolytics. 25:308. PubMed Montfort M, et al. 2004. J Immunol. 173:4084. PubMed Yang E, et al. 2016. J Immunol. 197: 934 - 941. PubMed Luck H, et al. 2019. Nat Commun. 10:3650. PubMed Yu M, et al. 2021. Molecular Cell. 81(6):1216-1230.e9. PubMed Clancy–Thompson E, et al. 2019. EMBO J. 38:e101260. PubMed Kiuchi M, et al. 2021. J Exp Med. 218:. PubMed Wang J, et al. 2022. Clin Transl Med. 12:e718. PubMed Sebina I, et al. 2016. PLoS Pathog. 12:e1005999. PubMed Lee J, et al. 2007. Nat Immunol. 8:181. PubMed Montes de Oca M, et al. 2016. PLoS Pathog. 12: 1005398. PubMed Webb LM, et al. 2020. J Clin Invest. 130:1683. PubMed Ren S, et al. 2022. Int J Biol Sci. 18:166. PubMed Tzeng TT, et al. 2022. NPJ Vaccines. 7:60. PubMed Xiao Z, et al. 2022. Mater Today Bio. 15:100297. PubMed Deng J, et al. 2021. EBioMedicine. 70:103505. PubMed Heckler M, et al. 2021. Cancer Discov. Online ahead of prin. PubMed Wang J, et al. 2020. J Hematol Oncol. 0.610416667. PubMed Spiljar M, et al. 2021. Cell Metab. 33:2231. PubMed Luo Z, et al. 2021. Int J Mol Sci. 22:. PubMed Tsai S, et al. 2018. Cell Metab. 28:922. PubMed Song X, et al. 2022. Transl Oncol. 15:101306. PubMed Li H, et al. 2021. Signal Transduct Target Ther. 6:389. PubMed Conforti A, et al. 2021. Mol Ther. S1525-0016:00466. PubMed Li X, et al. 2021. Front Cell Dev Biol. 9:647713. PubMed
RRID: AB_10897937 (BioLegend Cat. No. 505829) AB_2563105 (BioLegend Cat. No. 505830)
Structure: Cytokine; dimer; 40-80 kD (Mammalian)
Bioactivity: Antiviral/antiparasitic activities; inhibits proliferation; enhances MHC class I and II expression on APCs
Cell Sources: CD8+ and CD4+ T cells, NK cells
Cell Targets: T cells, B cells, macrophages, NK cells, endothelial cells, fibroblasts
Receptors: IFN-γRα (CDw119) dimerized with IFN-γRβ (AF-1)
Cell Type: Tregs
Biology Area: Cell Biology, Immunology, Neuroinflammation, Neuroscience
Molecular Family: Cytokines/Chemokines
Antigen References: 1. Fitzgerald K, et al. Eds. 2001. The Cytokine FactsBook. Academic Press, San Diego. 2. De Maeyer E, et al. 1992. Curr. Opin. Immunol. 4:321. 3. Farrar M, et al. 1993. Annu. Rev. Immunol. 11:571. 4. Gray P, et al. 1987. Lymphokines 13:151.
Regulation: Upregulated by IL-2, FGF-basic, EGF; downregulated by 1-α-25-Dihydroxy vitamin D3, dexamethasone
Gene ID: 15978
UniProt: View information about IFN-gamma on UniProt.org
Clone: XMG1.2
Regulatory Status: RUO
Other Names: Interferon-γ, Immune interferon, Type II interferon, T cell interferon, Macrophage-activating factor (MAF)
Isotype: Rat IgG1, κ
Q: What is the F/P ratio range of our BV421™ format antibody reagents?
A: It is lot-specific. On average it ranges between 2-4.